EFFICACY OF LENVATINIB TREATMENT IN ADVANCED HEPATOCELLULAR CARCINOMA
DOI:
https://doi.org/10.59354/ydth175.2025.428Từ khóa:
Lenvatinib, hepatocellular carcinoma, HCC, advanced stageTóm tắt
Background: Lenvatinib - a multi-target oral multi-kinase inhibitor with activity against multiple carcinogenesis pathways - was approved in 2018 as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). This study aimed to assess efficacy and the safety profile of lenvatinib therapy for patients with advanced HCC in real-world settings.
Objective: Evaluate the overall survival (OS), progression-free survival (PFS), disease control rate (DCR), and toxicity of lenvatinib in advanced HCC.
Patients and method: Retrospective descriptive study from 32 patients with advanced HCC to receive lenvatinib at Military Hospital 175 from January 2022 to July 2024.
Results: Median OS was 10.5 months [95% CI: 7 months- NA]. Median PFS was 8 months [95% CI: 6 months - NA], DCR was 71.9%. The most common toxicity was elevated aspartate aminotransferase (40.6%), of which grade 3-4 accounted for 3.1%.
Conclusion: Lenvatinib in the treatment of advanced HCC prolongs PFS and OS, has a favorable disease control rate and common toxicities were grade 1-2.
Tài liệu tham khảo
1. Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer.
2. Balogh J, Victor D III, Asham EH, et al. Hepatocellular Carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41–53.
3. Years of Kudo M, Izumi N, Sakamoto M, et al. Survival analysis over 28 173,378 patients Liver Cancer. 2016;5:190–7.
4. with Hepatocellular Carcinoma in Japan. Yamashita T., Kudo M., Ikeda K., et al. (2020). REFLECT – a phase 3 trial comparing efficacy and safety of levatinib to sorafenib for the treatment of unresectable Hepatocellular Carcinoma: an analysis of Japanese subset. J Gastroenterol, 55(1), 113-122.
5. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable Hepatocellular Carcinoma: a randomised phase 3 noninferiority trial. Lancet 2018;391:1163-1173.
6. Alsina A, Kudo M, Vogel A, et al. Effects of subsequent systemic anticancer medication following first-line lenvatinib: A post hoc responder analysis from the phase 3 REFLECT study in Unresectable Hepatocellular Carcinoma. Liver Cancer 2020;9:93-104.
7. Goh M.J., Oh J.H., Park Y., et al. (2021). Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea. LIC, 10(1), 52–62.
